Arcus biosciences, inc. announces executive changes

On september 10, 2019, bristol-myers squibb company and celgene corporation announced that kristen hege, md would assume a senior role within bms, contingent upon consummation of the pending merger between bms and celgene. given the overlapping pipeline between arcus biosciences, inc. and bms, bms’s conflict policies prohibit dr. hege from remaining a member of the company’s board of directors following the consummation of the merger, and dr. hege will therefore be required to tender her resignation as a director of the company. the merger between bms and celgene was consummated on november 20, 2019, and, consequently, dr. hege resigned from the board effective november 20, 2019. dr. hege did not serve on any board committees.
RCUS Ratings Summary
RCUS Quant Ranking